DDInter1086 DDInter1435
An alkylating agent of value against both hematologic malignancies and solid tumors.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lomustine {u} (Compound) treats {v} (Disease) brain cancer
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
Lomustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Lomustine {u} (Compound) causes {v} (Side Effect) Visual impairment
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Lomustine (Compound) treats brain cancer (Disease)
Lomustine (Compound) binds CYP3A4 (Gene)
Lomustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Lomustine (Compound) causes Visual impairment (Side Effect)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Lomustine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Lomustine may lead to a major life threatening interaction when taken with Lomitapide
Lomustine may lead to a major life threatening interaction when taken with Clozapine